This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of the da Vince Surgical System. Higher production costs are a woe.
Intuitive Surgical, Inc. (ISRG) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $323.77, marking a +0.67% move from the previous day.
Intuitive Surgical, Inc. (ISRG) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) closed at $334.74 in the latest trading session, marking a +1.67% move from the prior day.
Intuitive Surgical, Inc. (ISRG) Up 6.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott's (ABT) Organic Sales Grow Amid Spike in COVID Cases
by Zacks Equity Research
Within Nutrition, the robust year-over-year performance of Abbott's (ABT) U.S. pediatric and international adult nutrition arms drives the company in the third quarter.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the Healthcare, AST and Life Sciences segments is driving the top line for STERIS (STE).
Intuitive Surgical's (ISRG) Ion System Backed by Clinical Study
by Zacks Equity Research
Latest study results of Intuitive Surgical's (ISRG) Ion system indicate the potential for this technology to help safely biopsy small lung nodules.
Intuitive Surgical (ISRG) Q3 Earnings Match Estimates, Up Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect strong segmental performance.
Markets Up on Strong Q3 Earnings: NFLX, UAL, ISRG After the Bell
by Mark Vickery
The Dow marked its fifth straight day higher, while the S&P 500 gained +0.74% and the Nasdaq +0.71% on the day.
Intuitive Surgical, Inc. (ISRG) Q3 Earnings Meet Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 0.00% and 0.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Allscripts (MDRX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and various innovation milestones.
LHC Group (LHCG) Reports Impressive Preliminary Q3 Revenues
by Zacks Equity Research
Growth in LHC Group's (LHCG) revenues in the third quarter is likely to have been boosted by continued strength in its home health and hospice services.
Intuitive Surgical (ISRG) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Intuitive Surgical (ISRG) has been struggling lately, but the selling pressure may be coming to an end soon.
3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.
Allscripts' (MDRX) New AI-Based Offering to Improve Patient Care
by Zacks Equity Research
Allscripts' (MDRX) latest AI-based scheduling application is expected to provide improved patient care as well as increase operational efficiencies of the healthcare system.
Intuitive Surgical, Inc. (ISRG) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance at the Instruments & Accessories segment.
Here's Why You Should Retain Tandem Diabetes (TNDM) for Now
by Zacks Equity Research
Investors are optimistic about Tandem Diabetes (TNDM) owing to robust international pump shipments and product launches.
The Zacks Analyst Blog Highlights: Pfizer, American Tower Corp, Intuitive Surgical, Fidelity National Information Services and FedEx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, American Tower Corp, Intuitive Surgical, Fidelity National Information Services and FedEx
Top Analyst Reports for Pfizer, American Tower & Intuitive Surgical
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), American Tower Corporation (AMT), and Intuitive Surgical, Inc. (ISRG).
Intuitive Surgical, Inc. (ISRG) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ISRG) Outperforming Other Medical Stocks This Year?
Intuitive Surgical, Inc. (ISRG) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $334.94, marking a +1.48% move from the previous day.
4 Stocks to Watch as Demand for Surgical Robots Ready to Rise
by Kaustav Ghosh
Watch out for the likes of Asensus Surgical (ASXC), Stryker (SYK), Medtronic (MDT) and Intuitive Surgical (ISRG) as demand for surgical robots is set to rise, owing to the conveniences they offer.
Intuitive Surgical, Inc. (ISRG) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) closed at $1,028.47 in the latest trading session, marking a +1.42% move from the prior day.